Project Grant R21AI193493
Award Date
7/3/25
Completion Date
6/30/27
Dollars Obligated
$168K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This U01 Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the mechanism by which the hormone ghrelin confers radioprotection to the gastrointestinal (GI) system and to preclinically develop human ghrelin as a safe and effective mitigator for GI acute radiation syndrome (GI-ARS). The total funding amount is $586,240 over the period of December 5, 2024 to November 30, 2029. The research will be...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $597,518 to the Sloan-Kettering Institute for Cancer Research to conduct research on developing an anti-ceramide antibody as a countermeasure for gastrointestinal acute radiation syndrome (GI-ARS). The goal is to assess how acute protection of the microvasculature can facilitate regeneration of the intestinal stem cell compartment, mitigating both...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $552,787.00 to Old Dominion University and its affiliated research foundation (ODURF) to develop YK-4-250, a novel radiation mitigator targeting the renin-angiotensin system and reactive oxygen species signaling to treat gastrointestinal acute radiation syndrome (GI-ARS). The research aims to investigate the mechanisms underlying GI-ARS, assess...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $158,716 to Duke University to conduct research on epigenetic mechanisms involved in the regeneration of intestinal stem cells after severe radiation exposure. The goal is to identify key epigenetic regulators that could help mitigate the effects of gastrointestinal acute radiation syndrome (GI-ARS), which can result in high mortality following radiological...
This federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $170,800.00 to the New York Blood Center, Inc. to develop a novel radiation countermeasure that addresses sex-dependent radiation response. The research aims to understand the mechanisms underlying sex-specific effects in radiation response regulation and produce a countermeasure that mitigates radiation injuries in a sex-dependent manner. Key...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $157,500.00 to the University of California, Los Angeles (UCLA) to develop and test new radiation mitigator compounds based on the estrogen receptor beta (ER-beta) agonist DPN. The goal is to create orally bioavailable DPN analogues that can more effectively treat bone marrow, gastrointestinal, respiratory, and cardiovascular injuries caused by total-body...
The National Institutes of Health (NIH) awarded a $239,363 Project Grant under the Research Infrastructure Programs (CFDA 93.351) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. The grant aims to determine the radioprotective efficacy of dietary administration of highly radiation-resistant non-pathogenic fungi in the Drosophila model system. The research will evaluate if consumption of these fungal strains can increase resistance to acute radiation damage across...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) seeks to develop novel mitigators of gastrointestinal acute radiation syndrome (GI-ARS) by targeting the STING-clusterin (CLU) axis to promote regeneration of irradiated intestinal epithelium. The total award amount is $515,326, with a project period from December 2, 2024 to November 30, 2029. Key objectives include defining the mechanisms by which CLU...
This federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $158,500.00 to Trustees of Indiana University, doing business as Indiana University Indianapolis, to develop a novel non-pharmacological strategy to mitigate radiation-induced cardiotoxicity. The research aims to determine optimal parameters for a "protective wounding" approach, where a small subcutaneous incision after radiation exposure can...
The Department of the Army Medical Command awarded a $157,500 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 1, 2021 to May 31, 2022 to restore functional ARF tumor suppression in non-small cell lung carcinoma through the use of peptide mimics. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...